Laboratory Diagnosis of Tuberculosis

Guest Editor:

Dr. Luke T. Daum
LuJo BioScience Laboratory, 1747 Citadel Plaza, Suite 201, San Antonio, TX 78209, USA

Deadline for manuscript submissions:
31 May 2024

Message from the Guest Editor

Tuberculosis (TB), caused by the microorganism Mycobacterium tuberculosis (MTB), is the second leading infectious killer globally, following COVID-19. It remains a persistent threat, leading to new infections and re-infections on a worldwide scale. Compounding this challenge is the emergence of new strains of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB, which continue to be identified.

Recent advances in TB diagnosis, including culturing techniques, protein assays, and nucleic acid tests, have significantly elevated the precision of TB detection and treatment. Notably, innovations in point-of-care and decentralized TB tests have broadened the scope of TB diagnosis to reach new patients and access critical resource-challenged environments. In this Special Issue on TB, we invite the submission of manuscripts focusing on MTB detection and laboratory enhancements in TB diagnosis. This encompasses a wide range of topics, including, but not limited to, laboratory-based and point-of-care TB diagnostics, along with methodologies for identifying drug susceptibility markers from clinical samples. Your contributions are invaluable in advancing our understanding of TB.

Special Issue

Editor-in-Chief

Prof. Dr. Andreas Kjaer
Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (*Medicine, General & Internal*)

Contact Us